FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Sheila Miknyoczki

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Procedures

Physiology

Cell Divisions

Anatomy

Tumor Cells, Cultured

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Robert L Hudkins; Kathryn Hunter; Susan Jones-Bolin; John Mallamo; Sheila J Miknyoczki; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Edward R Bacon; Nadine C Becknell; Hong Chang; Ted L Underiner; Hugh Zhao; Allison L Zulli; Bruce Ruggeri
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Karen L Milkiewicz; Seetha Murthy; Damaris Rolon-Steele; Ted L Underiner; Linda R Weinberg; Candace S Worrell; Kelli S Zeigler; Lisa D Aimone; Albom Mark; Thelma S Angeles; Hong Chang; Jennifer V Grobelny; Jean Husten; Christine Losardo; Sheila J Miknyoczki; Bruce D Dorsey
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Craig A Zificsak; Jay P Theroff; Lisa D Aimone; Mark S Albom; Thelma S Angeles; Rebecca A Brown; Deborah Galinis; Jennifer V Grobelny; Torsten Herbertz; Jean Husten; Laura S Kocsis; Christine LoSardo; Sheila J Miknyoczki; Seetha Murthy; Damaris Rolon-Steele; Ted L Underiner; Kevin J Wells-Knecht; Candace S Worrell; Kelli S Zeigler; Bruce D Dorsey
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Sheila Miknyoczki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2012: Robert L Hudkins; Kathryn Hunter; Susan Jones-Bolin; John Mallamo; Sheila J Miknyoczki; Lisa D Aimone; Albom Mark; Thelma S Angeles; Mark A Ator; Edward R Bacon; Nadine C Becknell; Hong Chang; Ted L Underiner; Hugh Zhao; Allison L Zulli; Bruce Ruggeri
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Journal of medicinal chemistry 2012;55(2):903-13.
2011: Karen L Milkiewicz; Seetha Murthy; Damaris Rolon-Steele; Ted L Underiner; Linda R Weinberg; Candace S Worrell; Kelli S Zeigler; Lisa D Aimone; Albom Mark; Thelma S Angeles; Hong Chang; Jennifer V Grobelny; Jean Husten; Christine Losardo; Sheila J Miknyoczki; Bruce D Dorsey
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Bioorganic & medicinal chemistry 2011;19(21):6274-84.
2011: Craig A Zificsak; Jay P Theroff; Lisa D Aimone; Mark S Albom; Thelma S Angeles; Rebecca A Brown; Deborah Galinis; Jennifer V Grobelny; Torsten Herbertz; Jean Husten; Laura S Kocsis; Christine LoSardo; Sheila J Miknyoczki; Seetha Murthy; Damaris Rolon-Steele; Ted L Underiner; Kevin J Wells-Knecht; Candace S Worrell; Kelli S Zeigler; Bruce D Dorsey
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Bioorganic & medicinal chemistry letters 2011;21(2):660-3.
2010: Ted L Underiner; Torsten Herbertz; Sheila J Miknyoczki
Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.
Anti-cancer agents in medicinal chemistry 2010;10(1):7-27.
2007: Sheila J Miknyoczki; Hong Chang; Jennifer Grobelny; Sonya Pritchard; Candace Worrell; Natalie McGann; Mark A Ator; Jean Husten; James Deibold; Robert L Hudkins; Allison Zulli; Ralph E Parchment; Bruce Ruggeri
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Molecular cancer therapeutics 2007;6(8):2290-302.
2004: Mir Ahamed Hossain; Juliet C Russell; Sheila J Miknyoczki; Bruce Ruggeri; Bachchu Lal; John Laterra
Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy.
Annals of neurology 2004;55(5):660-7.
2003: Sheila J Miknyoczki; Susan Jones-Bolin; Sonya Pritchard; Kathryn Hunter; Hugh Zhao; Weihua Wan; Mark A Ator; Ronald Bihovsky; Robert L Hudkins; Sankar Chatterjee; Andres Klein-Szanto; Craig Dionne; Bruce Ruggeri
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Molecular cancer therapeutics 2003;2(4):371-82.
2002: Sheila J Miknyoczki; Weihua Wan; Hong Chang; Pawel Dobrzanski; Bruce Ruggeri; Craig Dionne; Karen Buchkovich
The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1924-31.
2001: Ashani T Weeraratna; Susan L Dalrymple; J C Lamb; Samuel R Denmeade; Sheila J Miknyoczki; Craig Dionne; John T Isaacs
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2237-45.
1999: Bruce Ruggeri; Sheila J Miknyoczki; J Singh; Robert L Hudkins
Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models.
Current medicinal chemistry 1999;6(9):845-57.
1999: Sheila J Miknyoczki; Hong Chang; Andres Klein-Szanto; Craig Dionne; Bruce Ruggeri
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2205-12.
1999: Sheila J Miknyoczki; Craig Dionne; Andres J P Klein-Szanto; Bruce Ruggeri
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Annals of the New York Academy of Sciences 1999;880():252-62.
1999: Sheila J Miknyoczki; D Lang; L Huang; Andres J P Klein-Szanto; Craig Dionne; Bruce Ruggeri
Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior.
International journal of cancer. Journal international du cancer 1999;81(3):417-27.
1998: D Lang; Sheila J Miknyoczki; L Huang; Bruce Ruggeri
Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.
Oncogene 1998;16(12):1593-602.
1996: Sheila J Miknyoczki; Andres Klein-Szanto; Bruce Ruggeri
Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer.
Critical reviews in oncogenesis 1996;7(1-2):89-100.
1995: Margie L Clapper; M Wood; K Leahy; D Lang; Sheila J Miknyoczki; Bruce Ruggeri
Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.
Carcinogenesis 1995;16(9):2159-65.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.